GHRH stimulates GH secretion from somatotroph cells of the anterior pituitary via a pathway that involves GHRH receptor activation of adenylyl cyclase and increased cAMP production. The actions of GHRH to release GH can be augmented by the synthetic GH secretagogues (GHS), which bind to a distinct G protein-coupled receptor to activate phospholipase C and increase production of the second messengers calcium and diacylglycerol. The stomach peptide ghrelin represents an endogenous ligand for the GHS receptor, which does not activate the cAMP signaling pathway. This study investigates the effects of GHS and ghrelin on GHRH-induced cAMP production in a homogenous population of cells expressing the cloned GHRH and GHS receptors. Each epitope-tagged receptor was shown to be appropriately expressed and to functionally couple to its respective second messenger pathway in this heterologous cell system. Although activation of the GHS receptor alone had no effect on cAMP production, coactivation of the GHS and GHRH receptors produced a cAMP response approximately twice that observed after activation of the GHRH receptor alone. This potentiated response is dose dependent with respect to both GHRH and GHS, is dependent on the expression of both receptors, and was observed with a variety of peptide and nonpeptide GHS compounds as well as with ghrelin-(1-5). Pharmacological inhibition of signaling molecules associated with GHS receptor activation, including G protein ␤␥-subunits, phospholipase C, and protein kinase C, had no effect on GHS potentiation of GHRH-induced cAMP production. Importantly, the potentiation appears to be selective for the GHRH receptor. Treatment of cells with the pharmacological agent forskolin elevated cAMP levels, but these levels were not further increased by GHS receptor activation. Similarly, activation of two receptors homologous to the GHRH receptor, the vasoactive intestinal peptide and secretin receptors, increased cAMP levels, but these levels were not further increased by GHS receptor activation. Based on these findings, we speculate that direct interactions between the GHRH and GHS receptors may explain the observed effects on signal transduction. (Endocrinology 143: 4570 -4582,  2002) 
pendent with respect to both GHRH and GHS, is dependent on the expression of both receptors, and was observed with a variety of peptide and nonpeptide GHS compounds as well as with ghrelin-(1-5). Pharmacological inhibition of signaling molecules associated with GHS receptor activation, including G protein ␤␥-subunits, phospholipase C, and protein kinase C, had no effect on GHS potentiation of GHRH-induced cAMP production. Importantly, the potentiation appears to be selective for the GHRH receptor. Treatment of cells with the pharmacological agent forskolin elevated cAMP levels, but these levels were not further increased by GHS receptor activation. Similarly, activation of two receptors homologous to the GHRH receptor, the vasoactive intestinal peptide and secretin receptors, increased cAMP levels, but these levels were not further increased by GHS receptor activation. Based on these findings, we speculate that direct interactions between the GHRH and GHS receptors may explain the observed effects on signal transduction. (Endocrinology 143: 4570 -4582, 2002) R EGULATION OF the GH axis is coordinated by the hypothalamic hormones GHRH and somatostatin. GHRH stimulates GH synthesis and secretion from the somatotroph cells of the anterior pituitary, whereas somatostatin inhibits GH secretion (1) . Recently, an endogenous GH secretagogue (GHS), ghrelin, was isolated from stomach (2) . Although GHRH and somatostatin regulate the ultradian rhythm of GH secretion, ghrelin appears to coordinate food intake with GH secretion (3) (4) (5) .
GHSs are a family of peptidergic and nonpeptidergic compounds that are potent stimulators of GH secretion. GHSs were developed based on the observation that metabolic fragments of opiate peptides stimulate GH secretion (6) . The earliest GHSs, which consisted of the pentapeptides TyrdTrp-Gly-Phe-Met-NH 2 and Tyr-dPhe-Gly-Phe-Met-NH 2 , had low potency in vitro and no activity in vivo (7, 8) . The first GHS to potently stimulate GH secretion both in vitro and in vivo was the synthetic hexapeptide, GH-releasing peptide-6 (GHRP-6) (9) . Subsequent generations of GHSs that include the peptidergic compounds GHRP-1 (10), GHRP-2 (11) , and hexarelin (12) and the nonpeptidergic compounds L692-429 (13, 14) , L-692-585 (15) , and MK-0677 (16) were generated to increase the half-life and bioavailability of these compounds.
Ghrelin, an endogenous GH secretagogue, is a 28-aminoacid peptide with a unique n-octanoyl modification on serine residue 3 that is necessary for its biological activity (2) . Ghrelin secretion rises before food intake (4), and it has been shown to stimulate food consumption (3) (4) (5) and adipogenesis (17) . In addition, ghrelin stimulates the secretion of insulin and gastric acid (18 -20) . Structure-function analysis of ghrelin has demonstrated that the first five amino acids of this peptide, including the n-octanoyl modification at position 3, are capable of binding the GHS receptor to stimulate the release of intracellular calcium (21) .
GHRH, ghrelin, and somatostatin act through G proteincoupled receptors (GPCRs) associated with distinct second messenger pathways. The GHRH receptor stimulates adenylyl cyclase (AC) to increase the production of the cellular second messenger cAMP. The GHS receptor, which binds ghrelin, activates phospholipase C (PLC), protein kinase C (PKC), and intracellular calcium mobilization (22) . Somatostatin receptors 2 and 5, the subtypes predominantly as-sociated with inhibition of GH secretion from the rat pituitary, reduce AC activity and stimulate the PLC/PKC second messenger pathway (23) (24) (25) .
In vivo, ghrelin synergizes with GHRH to stimulate a potentiated GH response (26) . Consistent with this finding, a potentiated GH response has been demonstrated in human studies after treatment with GHRH and GHRP-6 (8, 27) . Efforts to determine the mechanism responsible for this synergistic response have been confounded by the fact that GHSs act on both the hypothalamus and pituitary. One effect of the GHSs on the hypothalamus includes stimulating GHRH release (28) . Although it has been suggested that GHS-induced GHRH release is responsible for this synergism, no studies have provided convincing data to support this hypothesis. In fact, studies in cultured pituitary cells demonstrate synergistic GH and cAMP responses to GHRH and GHS treatments (13, 29, 30) . These findings suggest that the actions of GHSs on the pituitary, and presumably on the somatotroph cells, are sufficient to elicit, at least in part, these synergistic responses. Pituitary cultures are a heterogeneous cell population, and the pituitary cell type-specific expression of the GHRH and GHS receptors has yet to be fully characterized. Thus, it is unclear whether the potentiated cAMP and GH responses arise from the direct actions of GHRH and GHS on the somatotroph cells. It is possible that GHSs may stimulate other pituitary cell types to release a paracrine factor that could then elicit the potentiated responses in somatotroph cells. In this study we generated a cell model to investigate the effect of GHS on GHRH-stimulated cAMP production in a homogeneous cell population. Using cells expressing both the GHRH and GHS receptors, we demonstrate an effect of GHS on GHRH-induced cAMP production and investigate signaling pathways to characterize the mechanism responsible for the synergistic cAMP response.
Materials and Methods

Reagents and plasmids
The GHS compounds L692-429, L692-428, and L692-585 were provided by Dr. Scott Feighner of the Merck & Co. (Rahway, NJ). GHRP-6 was purchased from Sigma-Aldrich (St. Louis, MO). Ghrelin-(1-5) was purchased from Peptides International (Louisville, KY). The rat vasoactive intestinal peptide (VIP) (31) and secretin receptors (32) initially provided by Dr. S. Nagata (Osaka Bioscience Institute, Osaka, Japan) were subcloned into pcDNA3 downstream of the T7 promoter using the HindIII and XbaI sites (33) . The ␤ARK1 minigene construct in the pRK5 vector was provided by Dr. Robert Lefkowitz (Duke University, Durham, NC). The CD8-␤ARK construct was provided by Dr. J. Silvio Gutkind (NIH, Bethesda, MD).
Generation of the flag epitope-tagged GHS receptor
The rat GHS receptor was isolated from hypothalamic RNA by RT-PCR using oligonucleotides generated from the published sequence (GHS-R5Ј, GCGAATTCATGTGGAACGCGACCCC; GHS-R3Ј, GCTCT AGATCATGTGTTGATGCTCGAC). A flag epitope tag was added to the carboxyl terminus of the rat GHS receptor using PCR (GHS-R flag, GCTCTAGACCTTGTCATCGTCGTCCTTGTAGTCTGTGTTGATGCT-CGACTTTG). The rat GHS receptor was ligated into the pTracer-cytomegalovirus mammalian expression vector (Invitrogen, San Diego, CA) using the KpnI and XbaI restriction sites.
Generation of hemagglutinin (HA) epitope-tagged rat GHRH receptor
The amino terminus of the rat GHRH receptor was excised from RPR-comp18c in pcDNA-1 (34) using the restriction enzymes BamHI and ApaI, whereas the carboxyl terminus of the mouse GHRH receptor, including an HA epitope tag in pGEM5z, was excised with the restriction enzymes ApaI and XbaI. The amino and carboxyl termini were ligated into the pcDNA3.0 vector (Invitrogen) using the BamHI and XbaI restriction sites.
Transfections with the vaccinia-T7 RNA polymerase hybrid expression system
All experiments were performed using HeLa-T4 cells transfected with various receptor constructs using the vaccinia virus-T7 polymerase hybrid expression system (35) . Subconfluent monolayers of HeLa-T4 cells maintained in DMEM (Life Technologies, Inc., Grand Island, NY) supplemented with 5% fetal bovine serum (Life Technologies, Inc.) were infected with vaccinia virus vTF7. 
Metabolic labeling of transfected cells and immunoprecipitation of epitope-tagged receptors
HeLa-T4 cells grown in 35-mm plates were transfected with 5 g DNA/plate for 12-15 h, then washed twice with PBS. Cells were starved in cysteine/methionine-deficient DMEM (ICN Biomedicals, Inc., Irvine, CA) for 30 min and then labeled with 50 Ci Express (NEN Life Science Products, Boston, MA)/plate in the same medium for 3 h at 37 C in 5% CO 2 . The cells were harvested, washed twice with PBS, and resuspended in 400 l RIPA buffer [150 mm NaCl, 50 mm Tris-HCl (pH 7.5), 1% Nonidet P-40, 0.5% deoxycholic acid, and 0.1% sodium dodecyl sulfate] containing 0.1 mm phenylmethylsulfonylfluoride, 1 g/ml leupeptin, and 1 g/ml aprotonin. Cells were lysed through a series of four freezethaw cycles, and the lysates were centrifuged for 10 min to pellet residual cellular debris. The supernatant was separated into two fractions into which 1 g/ml of the HA-specific 12CA5 ascites fluid (a gift from Dr. Robert A. Lamb, Northwestern University) or the anti-M2 monoclonal antibody against the flag epitope (Sigma-Aldrich) was added. Antibodies were incubated overnight at 4 C on a hematology mixer. The following day 30 l of a 50% suspension of protein A-Sepharose beads (Amersham Pharmacia Biotech, Piscataway, NJ) in PBS were added to the tubes, and the incubation was continued for 45 min. The beads were washed seven times with 500 l cold RIPA buffer and once with cold wash buffer [50 mm Tris-HCl (pH 7.5), 150 mm NaCl, and 5 mm EDTA]. The beads were then resuspended in 40 l 2ϫ SDS-PAGE sample buffer [50 mm Tris-HCl (pH 6.8), 2% SDS, 10% glycerol, 100 mm dithiothreitol, and 0.1% bromophenol blue]. The samples were boiled for 5 min before separation by SDS-PAGE using a Tris-glycine buffer with the Benchmark Prestained Protein Ladder (Invitrogen) as size markers. The gels were fixed in 20% methanol/7% acetic acid for 30 min, saturated with glacial acetic acid twice for 5 min each time, impregnated with 22% (wt/vol) 2,5-diphenyl-ox-azole in acetic acid for 45 min, dried, and exposed to Kodak X-OMAT AR film (Eastman Kodak Co., Rochester, NY). Receptor expression levels were quantified using the software package Scion Image 1.6 (NIH).
against the flag epitope in PBS containing 0.1% saponin for 1 h at room temperature. After extensive washing, the coverslips were incubated with 2 g/ml fluorescein isothiocyanate-conjugated goat antimouse secondary antibody (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA) in PBS containing 0.1% saponin for 1 h at room temperature. After extensive washing with PBS, the coverslips were mounted in Vectashield (Vector Laboratories, Inc., Burlingame, CA). Photomicroscopy of cells was performed using a ϫ63 objective on a DM IRE2 inverted microscope (Leica Corp., Rockleigh, NJ) with equivalent exposure times.
Measurement of intracellular cAMP levels
HeLa-T4 cells were transfected in 12-well plates using 1 g DNA/ well overnight. The cells were washed twice in 1ϫ PBS and then incubated in serum-free DMEM (Life Technologies, Inc.) with 0.1 mm isobutylmethylxanthine for 20 min at 37 C. Hormones in freshly warmed medium were added to the cells, and the incubation was continued for another 20 min at 37 C. Medium was removed, and cells were lysed with ice-cold 0.1 n HCl for 10 min on ice. The lysates were neutralized in 150 l 50 mm Tris (pH 8.0) and 8 mm EDTA. Twenty-five microliters of neutralized lysate were used to assay cAMP in a competitive protein binding assay using [8- 3 H]cAMP (Amersham Pharmacia Biotech) as a tracer. Lysate, tracer, and binding protein were incubated on ice for 2 h, followed by the addition of 50 l activated charcoal solution [2.6% activated charcoal (Sigma-Aldrich), 50 mm Tris-HCl (pH 7.5), 4 mm EDTA, and 2% BSA]. Samples were centrifuged at 4 C for 2 min, and 100 l supernatant were drawn off. The protein-bound [8- 3 H]cAMP in the supernatant was measured by liquid scintillation counting using CytoScint (ICN Biomedicals, Inc.), and a linear standard curve was performed in each assay. The assays were performed with triplicate samples.
Measurement of intracellular calcium release
Fluorometry was used to measure the release of calcium from intracellular stores after GHRH treatment. Transfected cells were lightly trypsinized and washed with DMEM (Life Technologies, Inc.) containing 5% serum (Life Technologies, Inc.). The cells were then washed with loading buffer (145 mm NaCl, 5 mm KCl, 1 mm MgCl 2 , 10 mm HEPES, 10 mm glucose, 1 mm CaCl 2 , and 1% BSA containing 147 g/ml probenecid) and resuspended in 1.5 ml loading buffer containing 3.5 g of the calcium indicator fluo-3/AM (Molecular Probes, Inc., Eugene, OR). After incubation on a hematology mixer for 30 min in the dark, the cells were centrifuged at 400 ϫ g at 4 C for 1 min, washed in loading buffer to remove excess dye, repelleted, and resuspended in loading buffer supplemented with 1 mm CaCl and 1% BSA. Fluorometric emission at 530 nm from 1 ml transfected HeLa-T4 cells loaded with the calcium dye was monitored after treatment with 10 m hormone, using a PC1 photon counting spectrofluorometer (ISS, Champaign, IL) with the excitation wavelength set at 515 nm. Before ligand treatment, the basal emission from transfected HeLa-T4 cells was measured and averaged. In plotting the ligand-induced calcium response, the averaged basal emission value was subtracted from all emission values.
Luciferase assay
After transfection and treatment, cells were washed twice with cold PBS, then lysed in sample buffer [25 mm HEPES (pH 7.8), 15 mm MgSO 4 , 4 mm EGTA, 1 mm dithiothreitol, and 0.1% Triton X-100] on ice for 20 -30 min with gentle shaking. One hundred microliters of the cell lysates were added to 400 l assay buffer [25 mm HEPES (pH 7.8), 15 mm MgSO 4 , 4 mm EGTA, 1 mm dithiothreitol, 5 mm ATP, and 1 g/ml BSA], 100 l 1 mm luciferin (sodium salt) were added using an automatic injector, and emitted luminescence was measured using a 2010 luminometer (Analytical Bioluminescence, San Diego, CA) for 10 sec. Twenty microliters of the cell lysate were used for total protein determination using a protein assay reagent (Bio-Rad Laboratories, Inc., Richmond, CA).
Results
Expression of a HA epitope-tagged rat GHRH receptor and a flag epitope-tagged rat GHS receptor
To allow for detection of the GHRH and GHS receptor proteins, epitope tags were added to the carboxyl termini of the receptors. The GHRH receptor had a HA epitope tag, and the GHS receptor had a flag epitope tag. Both receptors were expressed in HeLa-T4 cells using the vaccinia-T7 RNA polymerase hybrid expression system (35) , and receptor protein expression was visualized through immunoprecipitation ( Fig. 1A) and immunofluorescence (Fig. 1B) . The GHRH and GHS receptors were found to be of the expected sizes of approximately 48 and 42 kDa, respectively ( Fig 1A) . For immunofluorescence, the HeLa-T4 cells were permeabilized with saponin after fixation with 1% paraformaldehyde to allow detection of the intracellular HA or flag epitope tags.
FIG. 1.
Expression of the HA epitope-tagged GHRH receptor and the flag epitope-tagged GHS receptor. A, Immunoprecipitation of the epitope-tagged receptor constructs. Equivalent amounts of protein from metabolically labeled HeLa-T4 cells transfected with the pcDNA3.0 vector, the HA-tagged GHRH receptor, the pTracer vector, or the flag epitope-tagged GHS receptor were immunoprecipitated using the 12CA5 ascites fluid to the HA epitope or the anti-M2 monoclonal antibody to the flag epitope. Molecular mass markers (in kilodaltons) are indicated on the left. B, Immunofluorescent localization of the receptor constructs. Immunofluorescence of HeLa-T4 cells transfected with pcDNA3.0, the HA-tagged GHRH receptor, pTracer, or the flag-tagged GHS receptor was performed using 12CA5 ascites fluid to the HA epitope and anti-M2 monoclonal antibody against the flag epitope. All incubations occurred in the presence of 0.1% saponin to permeabilize the cells. Photographs were taken with the same exposure length and magnification using an inverted fluorescence microscope.
Both receptors were detected predominantly in the perinuclear and cell surface regions.
Functional characterization of the epitope-tagged rat GHRH and GHS receptors
To ensure that the GHS receptor is functional, the release of intracellular calcium ( Fig. 2A) and activation of the MAPK pathway (Fig. 2B) were measured. HeLa-T4 cells transiently expressing the flag epitope-tagged GHS receptor were treated with the GHS agonist L692-429 or its inactive enantiomer L692-428. The release of intracellular calcium was measured using fluorometry with the calcium indicator dye fluo-3/AM. Untransfected HeLa-T4 cells were unresponsive to L692-429 treatment, whereas HeLa-T4 cells transiently expressing GHS receptors demonstrated an increase in fluorescent emission after L692-429 treatment. In contrast, treatment with the inactive enantiomer L692-428 had no effect on fluorescent emission from these transfected cells. As previously reported, treatment with GHRH had no effect on intracellular calcium release from HeLa-T4 cells transiently expressing the HA epitope-tagged GHRH receptor (34) . An Elk-1 reporter gene-based assay was used to measure GHS activation of the MAPK pathway. This system includes a GAL4 UAS luciferase plasmid and a unique trans-activator plasmid that expresses a fusion protein consisting of the activation domain for Elk1 linked to the yeast GAL4 DNAbinding domain. HeLa-T4 cells were transfected with these two plasmids and the GHS receptor. A significant increase in luciferase activity after L692-429 treatment was seen, suggesting that activation of the GHS receptor stimulates the MAPK pathway. To determine whether GHS receptor activation has an effect on cAMP production, cAMP levels were measured in response to ligand treatment (Fig. 2C) . There was no increase in cAMP levels after activation of the GHS receptor, although as expected, cAMP levels were elevated in response to GHRH receptor activation.
Potentiation of GHRH-induced cAMP production by GHS receptor activation
To investigate the effect of GHS potentiation on GHRHinduced cAMP production in a homogeneous cell population, HeLa-T4 cells were transfected with both the GHRH and GHS receptors. Levels of cAMP were measured in the transfected cells after treatment with GHRH, L692-429, or both GHRH and L692-429 (Fig. 3A) . There was an increase in cAMP levels in response to treatment with 1 nm and even more so with 100 nm GHRH. In contrast, the levels of cAMP were unaffected by treatment with 10 or 50 m L692-429. Interestingly, cotreatment with GHRH and L692-429 elicited a potentiated cAMP response in the transfected cells. L692-429 treatment with 1 nm GHRH resulted in cAMP levels 3.3 times greater than those in response to GHRH treatment alone, whereas 100 nm GHRH plus L692-429 elicited a response 2.4 times greater than that with GHRH treatment alone. In the absence of the GHS receptor, there was no potentiation of the cAMP response (Fig. 3A) . To determine receptor expression levels in the cotransfection experiments the GHRH and GHS receptors were immunoprecipitated from protein lysates of metabolically labeled HeLa-T4 cells using monoclonal antibodies to the HA-and flag epitope tags. Expression of each receptor was somewhat reduced in cells cotransfected with both receptors compared with that in cells transfected with individual receptors. GHRH receptor number was reduced to 63% of the control value, and GHS FIG. 3. GHS potentiation of GHRHinduced cAMP production. A, Measurement of cAMP production in HeLa-T4 cells transfected with the receptor constructs. HeLa-T4 cells were transfected with the GHRH and GHS receptors or with the GHRH receptor and the pTracer vector (indicated by underlining and italics). The cells were stimulated with increasing concentrations of GHRH, L692-429, or both GHRH and L692-429. Transfections were performed in triplicate, and the error bars represent the SEM. Statistical analysis was performed using paired t test (**, P Ͻ 0.01; ***, P Ͻ 0.005). B, Immunoprecipitation of the epitope-tagged GHRH and GHS receptors. Equivalent amounts of protein from metabolically labeled HeLa-T4 cells transfected with the GHRH and GHS receptors (indicated by plus) were immunoprecipitated using antibodies to the HA or flag epitope tags (indicated by plus) and separated by SDS-PAGE on a 10% gel. Molecular mass markers (in kilodaltons) are indicated on the right.
receptor was reduced to 78% of control value in the cotransfection experiment (Fig. 3B) .
A variety of GHSs potentate GHRH-induced cAMP production
As the GHSs are a family of structurally distinct compounds, and alternative isoforms of the GHS receptor have been recently characterized (36, 37) , the effects of various synthetic and natural GHS ligands on GHRH-induced cAMP production were assessed. Cotreatment with GHRH and L692-585, L692-429, GHRP-6, or an analog of the endogenous GHS ligand, ghrelin-(1-5), produced a similar 2-fold increase in cAMP production beyond that attained with GHRH alone (Fig. 4) . In contrast, cotreatment with the inactive GHS compound, L692-428, did not further increase cAMP production.
Dose-response curves of ghrelin-induced cAMP potentiation
To determine the concentration of ghrelin sufficient to potentiate GHRH-induced cAMP production, cAMP levels were measured in transfected cells treated with 100 nm GHRH and increasing concentrations of ghrelin-(1-5) (Fig.  5A ). GHRH-induced cAMP production was potentiated by ghrelin-(1-5) at concentrations ranging from 10 nm to 10 m, but no effect was seen at 1 nm. To determine whether the ability of ghrelin to potentiate cAMP production is dependent on the concentration of GHRH, cAMP levels were measured in response to treatment with 1 m ghrelin-(1-5) and increasing concentrations of GHRH (Fig. 5B) . Although ghrelin-(1-5) potentiated cAMP production in response to treatment with GHRH at concentrations of 1, 10, and 100 nm, lower concentrations of GHRH failed to stimulate cAMP levels.
FIG. 4. Potentiation of GHRH-induced cAMP production by various
GHSs. Production of cAMP was measured in HeLa-T4 cells transfected with the GHRH and GHS receptors and stimulated with GHRH or GHRH plus different GHSs. Conditions were repeated in triplicate, and the error bars represent the SEM. Statistical analysis was performed using paired t test (**, P Ͻ 0.01; ***, P Ͻ 0.005).
FIG. 5. Dose-response curves of ghrelin potentiation of GHRHinduced cAMP production. A, Measurement of cAMP production in
HeLa-T4 cells transfected with both receptors in the presence of increasing concentrations of ghrelin-(1-5). Cells were transfected with the GHRH and GHS receptors and stimulated with 100 nM GHRH and increasing concentrations of ghrelin- (1-5) . B, Measurement of cAMP production in HeLa-T4 cells transfected with both receptors in the presence of increasing concentrations of GHRH. Cells transfected with both receptors were stimulated with 1 M ghrelin-(1-5) and increasing concentrations of GHRH. For A and B, conditions were repeated in triplicate, and the error bars represent the SEM. Statistical analysis was performed using paired t test (*, P Ͻ 0.05; **, P Ͻ 0.01; ***, P Ͻ 0.005).
GHS potentiates the GHRH-induced cAMP response through a PKC-independent mechanism
Previous reports suggested that GHS activation of PKC resulted in potentiation of GHRH-induced cAMP production (30) . To address the role of PKC in mediating this response, cAMP levels were measured in response to ligand stimulation after pretreatment with the PKC inhibitors GF109203X, RO31-8220, and staurosporine. GHRH-induced cAMP production is potentiated by GHS in the presence of each of these PKC inhibitors. cAMP production is potentiated 2.2-fold in the presence of GF109203X, 1.8-fold in the presence of RO31-8220, and 2.6-fold in the presence of staurosporine (Fig. 6, A  and B) . GHS continues to potentiate GHRH-induced cAMP production in the presence of a wide range of concentrations of these three PKC inhibitors (GF109203X, 1-100 m; staurosporine, 0.01-1 m; RO31-8220, 1-100 m). The exception was 100 m GF109203X, where there was no cAMP response to GHRH alone, suggesting that this high concentration of GF109203X had a toxic effect on the cells. Additionally, cAMP levels were measured after PKC was down-regulated following 12-O-tetraphorbol 12-myristate 13-acetate (TPA) pretreatment for 12 h. Although the overall cAMP response after TPA pretreatment was attenuated, the GHRH-induced cAMP response was potentiated 2.4-fold by GHS cotreatment (Fig. 6A) . Similar results were observed in HeLa-T4 cells pretreated with TPA at concentrations of 60 nm, 3 nm, and 300 pm. To verify PKC inhibition by GF109203X in these cells, the activity of a TPA-responsive promoter-luciferase reporter construct (␤A-Nae1) (38) was measured after TPA stimulation in the presence of GF109203X (Fig. 6C) . GF109203X successfully inhibited TPA activation of the ␤A-Nae1 promoter construct, suggesting that PKC activity was blocked by FIG. 6 . GHS potentiation of GHRH-induced cAMP production in the presence of PKC inhibitors. A, Measurement of cAMP production in transfected HeLa-T4 cells in the presence of a PKC inhibitor or after PKC down-regulation. Cells were transfected with the GHRH and GHS receptors and stimulated with 100 nM GHRH or 100 nM GHRH plus 10 M L692-429 after 30-min pretreatment with 10 M GF109203X or 12-h pretreatment with 30 nM TPA. B, Measurement of cAMP production in transfected HeLa-T4 cells in the presence of PKC inhibitors. Cells were transfected with both receptors, pretreated with 10 M RO31-8220 and 100 nM staurosporine for 30 min, and then stimulated with ligand. For the no treatment and RO31-8220 pretreatment conditions, the cells were stimulated with 100 nM GHRH or 100 nM GHRH plus 10 M L692-585. For the staurosporine pretreatment condition, the cells were stimulated with 100 nM GHRH or 100 nM GHRH plus 10 M L692-429. C, Measurement of luciferase production by the ␤A-Nae1 reporter construct in response to TPA in the presence of GF109203X. The ␤A-Nae1 construct has three TPA responsive elements (TRE) located at Ϫ147, Ϫ194, and Ϫ534. HeLa-T4 cells were transfected with the ␤A-Nae1 construct for 6 h, allowed to recover overnight, and then stimulated with 60 nM TPA in the presence or absence of 10 M GF109203X. D, Measurement of cAMP production in HeLa-T4 cells after GHRH cotreatment with GHRP-6, L692-429, or TPA for 20 min. Cells were transfected with both receptors and then stimulated with 100 nM GHRH plus 10 M L692-429, 2 M GHRP-6, or 24 M TPA. For A-D, conditions were repeated in triplicate, and the error bars represent the SEM. Statistical analysis was performed using paired t test (*, P Ͻ 0.05; **, P Ͻ 0.01; ***, P Ͻ 0.005).
the 30-min pretreatment with 10 m GF109203X. Finally, to determine whether PKC activation was sufficient to potentiate the GHRH-induced cAMP response in these cells, cAMP production was measured in cells stimulated with GHRH and L692-429, GHRP-6, or TPA for 20 min (Fig. 6D) . Although cAMP production was potentiated 2-fold in response to L692-429 treatment and 2.3-fold in response to GHRP-6 treatment, treatment with TPA had no significant effect on GHRH-induced cAMP production. These findings demonstrate that PKC activation after acute treatment with TPA is not sufficient to potentiate GHRH-induced cAMP production.
GHS potentiation of GHRH-induced cAMP production is unaffected by PLC inhibition
As previously mentioned, the GHS receptor couples to a G q or G 11 class G protein to activate the PLC signaling pathway. To determine the role of PLC in mediating the potentiated cAMP response, cAMP levels were measured in transfected HeLa-T4 cells after pretreatment with the PLC inhibitor, U73122. GHS treatment potentiated GHRHinduced cAMP production 1.9-fold in untreated cells and 1.7-fold in U73122-pretreated cells (Fig. 7A) . GHS continued to potentiate GHRH-induced cAMP production by at least 2-fold after pretreatment with U73122 at concentrations ranging from 1-100 m. To ensure that U73122 pretreatment successfully inhibited PLC, the release of intracellular calcium was measured in cells expressing the GHS receptor. Intracellular calcium release was reduced to 37.4% of the control value in cells pretreated with U73122 (Fig. 7B) . The findings that PLC inhibition substantially reduced calcium release, but had no significant effect on cAMP potentiation, suggest that PLC and its second messenger pathways do not mediate this response.
GHS potentiation of GHRH-induced cAMP production is unaffected by sequestration of the G protein ␤␥-subunits
The G protein ␤␥-subunits can activate adenylyl cyclase types II, IV, and VII (39, 40) . To determine whether the G protein ␤␥-subunits coupled to the GHS receptor mediate the potentiated cAMP response, cAMP levels were measured in cells cotransfected with a ␤␥ sequestrant, the ␤-adrenergic receptor kinase 1 carboxyl terminus minigene (␤ARK1-ct) (41) . HeLa-T4 cells were transfected with the GHRH and GHS receptors along with the ␤ARK1-ct construct. Transfected cells were treated with 100 nm GHRH or 100 nm GHRH plus 10 m L692-429. In the presence of the ␤␥ sequestrant, GHS treatment still potentiated GHRH-induced cAMP production (Fig. 8A) . GHS treatment potentiated cAMP production 3-or 1.9-fold in cells coexpressing the pTracer vector or the ␤ARK1-ct construct, respectively. These findings suggest that GHS potentiates GHRH-induced cAMP production through a mechanism independent of the G protein ␤␥-subunits.
Similar experiments were performed using a different ␤␥ sequestrant, the CD8-␤ARK. This ␤␥ sequestrant is a Myc epitope-tagged ␤ARK fused to the amino terminus of the CD8 lymphocyte-specific receptor, which includes four membrane-spanning domains that target the protein to the plasma membrane, where the G protein ␤␥-subunits are tethered (42) . HeLa-T4 cells were transfected with the GHRH and GHS receptors in combination with the pcDNA3 vector or CD8-␤ARK. GHS continued to potentiate GHRH-induced cAMP production in the presence of CD8-␤ARK (Fig. 8B) . The production of cAMP was potentiated 2-fold in cells coexpressing the vector and 2.3-fold in cells coexpressing CD8-␤ARK. To verify that the CD8-␤ARK protein is expressed, immunoprecipitation of protein lysates from metabolically FIG. 7 . GHS potentiation of GHRH-induced cAMP production in the presence of a PLC inhibitor. A, HeLa-T4 cells were transfected with both receptor constructs, pretreated with 10 M U73122 for 20 min, and then stimulated with 100 nM GHRH or 100 nM GHRH plus 10 M L692-585. Conditions were repeated in triplicate, and the error bars represent the SEM. Statistical analysis was performed using paired t test (***,P Ͻ 0.005). B, Measurement of intracellular calcium release. HeLa-T4 cells were transfected with the GHS receptor, pretreated with 10 M U73122 for 10 min, and then stimulated with 1 M ghrelin-(1-5). The release of intracellular calcium was indicated by an increase in fluorescent emission at 530 nm. The arrows represent the onset of ligand treatment. Areas under the curve were calculated and used to assess U73122 inhibition of calcium release, which was reduced to 37.4% of control levels.
labeled HeLa-T4 cells was performed using an antibody against the Myc epitope tag (Fig. 8C) . The Myc epitopetagged CD8-␤ARK was found to be of the expected size of about 46 kDa.
Effect of GHS treatment on VIP-, secretin-, or forskolininduced cAMP production
To address whether GHS could potentiate cAMP production induced by other related GPCRs, cAMP levels were measured in HeLa-T4 cells in which the receptors for VIP or secretin substituted for the GHRH receptor. Like the GHRH receptor, the VIP and secretin receptors stimulate AC activity and belong to the B-III subfamily of GPCRs (43) . The amino acid sequences of the VIP and secretin receptors are 40% and 35% identical with that of the GHRH receptor (33) . The level of cAMP in cells expressing the GHS and VIP receptors was slightly increased after cotreatment with both ligands compared with VIP alone, but this increase was not statistically significant (Fig. 9A) . Likewise, no difference in cAMP levels was detected in cells expressing the GHS and secretin receptors after treatment with secretin or secretin plus GHS (Fig. 9B) . These findings indicate that GHSs exhibit some degree of selectivity in potentiating cAMP production stimulated by the GHRH receptor.
Forskolin is a direct activator of adenylyl cyclase (44) . To determine whether GHS treatment could potentiate forskolin-induced cAMP production, cells transfected with the GHRH and GHS receptors were stimulated with forskolin or forskolin plus GHS (Fig. 9C ). Cotreatment with GHS had no effect on forskolin-induced cAMP production, suggesting that GHSs may interact with the GHRH signaling pathway upstream of AC activation.
Discussion
This paper reports that in a homogeneous cell population expressing the GHRH and GHS receptors GHRH-induced cAMP production is potentiated by GHS cotreatment. These findings demonstrate that GHRH and GHS act directly on the same cells to potentiate the second messenger pathway coupled to the GHRH receptor. Previous studies in dispersed rat anterior pituitary cells have shown that GHRP-6 and L692-429 treatments potentiate GHRH-induced cAMP production approximately 1.5-fold (13, 29, 30) . In the transfected HeLa-T4 cells, GHS potentiation of GHRH-induced cAMP production was within the range of 1.5-to 3-fold. This response was seen with a variety of GHSs, including the benzolactam compounds L692-429 and L692-585, the peptide GHRP-6, and an analog of the endogenous GHS, ghrelin-(1-5). These GHSs vary in binding affinity for the GHS receptor and the 50% effective concentration values for GH secretion. Ghrelin has the greatest binding affinity for the receptor, followed by L692-585, GHRP-6, and L692-429 (45, 46) , and the 50% effective concentration values of GH secretion for these GHSs are in the nanomolar range.
Given the pivotal importance of cAMP in mediating the ability of GHRH to stimulate GH synthesis and secretion, potentiation of cAMP production by GHS is likely to explain the synergism between GHRH and GHS in GH release observed in pituitary cells. Therefore, signaling studies were pursued in this model system to investigate GHS potentiation of GHRH-induced cAMP production. The GHS receptor signals through the PLC second messenger pathway. Early signaling studies suggested that PKC mediated GHS potentiation of GHRH-induced cAMP production and GH secretion (30, 47) . One study found that treating rat pituitary cells FIG. 8 . GHS potentiation of GHRH-induced cAMP production in the presence of G protein ␤␥ sequestrants. A, Levels of cAMP were measured in HeLa-T4 cells expressing the GHRH and GHS receptors and a ␤␥ sequestrant, the carboxyl terminus of the ␤-adrenergic receptor kinase. Cells expressing both receptors were cotransfected with pTracer or ␤ARK1-ct in pTracer and then stimulated with 100 nM GHRH or 100 nM GHRH plus 10 M L692-429 for 20 min. B, Similar experiments were repeated using a different ␤␥ sequestrant, the CD8-␤ARK. HeLa-T4 cells expressing both receptors were cotransfected with the pcDNA3.0 vector or the CD8-␤ARK construct. Cells were stimulated with 100 nM GHRH in the presence or absence of 10 M L692-429 for 20 min. For A and B, the conditions were repeated in triplicate, and the error bars represent the SEM. Statistical analysis was performed using paired t test (*, P Ͻ 0.05; ***, P Ͻ 0.005). C, Expression of CD8-␤ARK was determined by immunoprecipitation of protein lysates using the monoclonal antibody against the Myc epitope tag.
with the phorbol ester PMA potentiated GHRH-induced cAMP production and GH secretion in a similar manner as GHRP-6 treatment (30) . Furthermore, the potentiated cAMP and GH responses were eliminated by down-regulating PKC (30) . In a separate study, the PKC inhibitor phloretin blocked GHS potentiation of GH secretion from somatotroph tumor cells expressing gsp oncogenes (47) . These oncogenes are translated into G␣ s proteins that lack endogenous GTPase activity, thereby resulting in constitutive activation of adenylyl cyclase and elevated levels of cAMP. The findings from these studies suggest that PKC may bridge the GHS and GHRH signaling pathways. In our model system, PKC inhibition or down-regulation had no effect on the ability of GHSs to potentiate GHRH-induced cAMP production. The PKC inhibitors GF109203X, RO31-8220, and staurosporine did not hinder the ability of GHS to potentiate the cAMP response. In addition, cAMP production was potentiated by GHS even after PKC down-regulation following a 12-h pretreatment with 30 nm TPA. In contrast, PKC down-regulation following a 24-h pretreatment with 1 m PMA inhibited the potentiating effect of GHS on GHRH-induced cAMP production and GH secretion in dispersed rat anterior pituitary cells (30) . The differences between these findings may reflect differences in the cell backgrounds or concentration/duration of the phorbol ester pretreatment. Finally, acute TPA treatment to activate PKC is unable to mimic the potentiating effect of GHS on GHRH-induced cAMP production. These results suggest that GHSs potentiate GHRH-induced cAMP production through a PKC-independent mechanism in this homogeneous population of cells expressing the cloned GHRH and GHS receptors.
GHS also potentiated GHRH-induced cAMP production in the presence of a PLC inhibitor. Inhibiting PLC should attenuate the entire downstream signal transduction pathway, including PKC activation and intracellular calcium mobilization. Like PKC, some Ca 2ϩ /calmodulin isoforms can activate adenylyl cyclase, thereby providing an additional mechanism for cross-talk between the PLC/PKC and AC/ cAMP signaling pathways. Adenylyl cyclase I, III, and VIII are activated by calmodulin (48 -50) . We confirmed inhibition of PLC by measuring intracellular calcium mobilization after activation of the GHS receptor. Although the calcium response to ghrelin stimulation was not completely eliminated, it was greatly attenuated, suggesting that PLC activity was largely inhibited. Yet, no effects on GHS potentiation of the cAMP response were observed under these conditions. Some ␤␥-subunits of the heterotrimeric G protein can increase cAMP production. Specifically, these ␤␥-subunits interact with the carboxyl-half of adenylyl cyclase types II and IV to augment G␣ s -induced AC activity 10-fold (39) . A recent study reported the involvement of the G protein ␤␥-subunits in the synergistic activation of PKA signaling by the D2 dopamine and A2 adenosine receptors (51) . However, in transfected HeLa-T4 cells coexpressing two different ␤␥ sequestrants, GHSs still potentiate GHRH-induced cAMP production, suggesting that the ␤␥-subunits are not involved in mediating the effect of GHS on cAMP production.
Cotreatment with GHS did not potentiate cAMP production in response to activation of other stimulatory G proteincoupled receptors belonging to the B-III subfamily. The VIP and secretin receptors have, respectively, 40% and 35% amino acid sequence identity with the GHRH receptor (33) . The finding that VIP-or secretin-induced cAMP production is not affected by GHS cotreatment suggests that the actions of the GHS receptor are somewhat selective for the GHRH receptor. However, a recent report demonstrated that GHS can potentiate cAMP production stimulated by the D1 dopamine receptor in an in vitro model system of HEK293 cells expressing both receptors (52) . Thus, it appears that the GHS receptor may more broadly impact cAMP signaling pathways activated by other G protein-coupled receptors. It remains to be determined whether similar or distinct mechanisms of interaction are used in these two systems.
Many studies have found that disruption of GHRH or its receptor reduces or completely eliminates the ability of GHSs to stimulate GH secretion. In rats, GHS-induced GH secretion was effectively blocked after GHRH antiserum treatment (10) . In ovine pituitary cells, a GHRH receptor antagonist inhibited GH secretion induced by GHRP-2 (53). Similar findings were reported in human studies in which the GHRH antagonist (N-Ac-Tyr 1 ,d-Arg 2 )GHRH-(1-29)NH 2 inhibited most of the GH response to GHRP-6 (54). Furthermore, the little mouse is resistant to GHS stimulation, suggesting that a functional GHRH receptor is necessary for GHS-induced GH secretion (55) . A similar finding has been reported in a case study of patients with a homozygous mutation in the GHRH receptor gene. This study reported that an injection of hexarelin did not elevate plasma GH levels in these patients (56) . Based on these findings, it has been suggested that GHS actions on the pituitary to release GH are dependent upon a functional GHRH receptor. The dependence of GHS signaling on the GHRH receptor may be mechanistically related to the synergistic effects of these two signaling pathways observed in our study.
Our signaling studies establish that blockade of the known signaling pathways downstream of GHS receptor activation fails to inhibit potentiation of GHRH receptor signaling. One plausible explanation for these results is that there is a direct interaction of the two receptors. Recent studies have shown that GPCRs can homo-or heterodimerize such that the characteristics of the receptor complexes, including binding, internalization, and signaling, are different from the characteristics of each receptor individually. Often the signaling of GPCR heterodimers results in potentiation of the second messenger pathways associated with each receptor in the complex. Both the dopamine and somatostatin receptors couple to inhibitory G proteins. In a heterodimer complex, inhibition of cAMP production by the dopamine and somatostatin receptors is potentiated (57) . Likewise, heterodimers of the ␦ and opioid receptors potentiate inhibition of cAMP production (58) . Heterodimerization of the bradykinin receptor, a G q protein-coupled receptor, and the angiotensin receptor, a GPCR that binds G i and G q proteins, potentiates angiotensin-induced G i turnover and inositol phosphate production (59) .
The findings from signaling studies identifying dominant negative GHRH receptors also provide support for the proposal that GHRH receptors form dimers. In two separate studies, coexpression of the GHRH receptor with a truncated receptor diminished GHRH-induced cAMP production (60, 61) . Furthermore, the binding of GHRH was reduced by coexpression of this truncated receptor (61) . One explanation for this effect is that the truncated receptor is forming a homodimer or homooligomer complex with the GHRH receptor, such that GHRH binding and signaling are attenuated. In addition to forming homodimers, we speculate that the GHRH receptor may be forming heterodimers with the GHS receptor. However, our preliminary studies using chemical cross-linking and immunoprecipitation have not detected heterodimer formation between the GHRH and GHS receptors. There may be technical limitations to detecting such heterodimers, including very low stoichiometry of dimer formation, instability of the dimers during the immunoprecipitation step, or inaccessibility of the epitope tags in a dimeric complex. Alternatively, the observed synergy may be independent of direct receptor interaction and may involve alterations in unidentified components of the signaling pathway leading to cAMP production and GH secretion. The model system here should facilitate further investigation to distinguish between these possible mechanisms of receptor synergy.
